Benjamin Shykind, PhD
Dr. Shykind is the Director of Neuroscience at MeiraGTx, a clinical-stage biotechnology company pioneering the use of gene therapy to transform the lives of patients suffering from acquired and inherited disorders, including devastating neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Prior to joining MeiraGTx, Dr. Shykind was an Assistant Professor at Weill Cornell Medicine in Qatar where his research focused on the genetic and cellular mechanisms underlying the development of neuronal diversity in the mammalian nervous system. Dr. Shykind holds a B.A. in biochemistry from Columbia College, Columbia University and earned a Ph.D. in biology from the Massachusetts Institute of Technology. He completed postdoctoral training at the College of Physicians and Surgeons, Columbia University, in the Department of Biochemistry and Molecular Biophysics